title: New lipid-lowering drugs: an update.
abstract: Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. Statins form the basis of care but are not able to treat all aspects of dyslipidaemia. Many novel therapeutic compounds are being developed. These include additional therapeutics for low-density lipoprotein cholesterol, for example, thyroid mimetics (thyroid receptor beta-agonists), antisense oligonucleotides or microsomal transfer protein inhibitors (MTPI); triglycerides, for example, novel peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase-1 inhibitors and high-density lipoprotein cholesterol (HDL-C), for example, mimetic peptides; HDL delipidation strategies and cholesterol ester transfer protein inhibitors and modulators of inflammation, for example, phospholipase inhibitors. Gene therapy for specific rare disorders, for example, lipoprotein lipase deficiency using alipogene tiparvovec is also in clinical trials. Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments as possible synergies exist between new and established compounds for the treatment of atherosclerosis.
authors.affiliation: Metabolic Medicine/Chemical Pathology, St. Thomas' Hospital Campus, London, UK. anthony.wierzbicki@kcl.ac.uk
authors.forename: A S
authors.initials: AS
authors.lastname: Wierzbicki
authors.forename: T C
authors.initials: TC
authors.lastname: Hardman
authors.forename: A
authors.initials: A
authors.lastname: Viljoen
mesh_terms: D000101:Acetyl-CoA C-Acetyltransferase / Q000037:antagonists & inhibitors; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000187:drug effects; D004338:Drug Combinations; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008082:Lipotropic Agents / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000037:antagonists & inhibitors; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors; D014280:Triglycerides / Q000037:antagonists & inhibitors
chemical_list: D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D004338:Drug Combinations; D000960:Hypolipidemic Agents; D008082:Lipotropic Agents; D016376:Oligonucleotides, Antisense; D047492:Peroxisome Proliferator-Activated Receptors; D014280:Triglycerides; C106092:microsomal triglyceride transfer protein; D000101:Acetyl-CoA C-Acetyltransferase; D013186:Farnesyl-Diphosphate Farnesyltransferase; D043484:Proprotein Convertases